Scientists will be able to detect cancer earlier from blood samples after advances were made in detecting microRNA molecules using gold-plated nanoparticles.
UNSW researchers have discovered a new way to detect ultralow levels of microRNA in a blood sample which could make diagnosis of cancer and other illnesses quicker and more efficient.
The research team used nanoparticles to latch on to the targeted microRNAs (miRNAs) which enabled them to be easily extracted. One of the main benefits was that it was effective even when the miRNA was in minuscule amounts in the blood sample. Previously, a much larger sample was needed to extract similar amounts.
MicroRNAs are short RNA molecules that target some messenger RNAs (genetic material used to synthesise proteins) to prevent them from coding for a specific protein. Impaired miRNA activity has been linked with the formation of cancerous tumours as well as metastasis, the spread of cancer to other parts of the body.
Scientia Professor Justin Gooding said the nanoparticles are, in effect, dispersible electrodes. When circulated through the blood they capture the miRNA before a magnet is used to recapture the nanoparticles with the newly attached microRNA.
“Now we get more of the microRNA because the dispersible electrodes capture nearly everything in the sample,” Professor Gooding said.
“Because the capture is so effective, we get higher sensitivities and can detect much lower limits.
“And since we bring them back to the electrode under a magnet, our response time is much faster.”
One of the advantages of being quicker is that it will cost less.
“It could be orders of magnitude cheaper. Our method takes 30 minutes compared with almost 12 hours for quantitative polymerase chain reaction,” Professor Gooding said.
Key to the new technology is not just the ability to detect lower concentrations of miRNA but the ability to detect a broad range of concentrations.
“This is really important to determine whether the levels of different microRNAs have increased or decreased,” Professor Gooding said.
“We can do this very quickly compared with the gold-standard nucleic acid amplification methods. And we can do it in unprocessed blood.
“What this means is the technology has the potential to determine the levels of microRNA just from a finger prick test.”
Professor Gooding said he would expect the technology to be available within three years, pending regulatory approvals.
The new diagnostic technique follows on the heels of a similar advance made by another UNSW research team exploring cancer detection in the blood.
In that study, published in Nature Communications, a team of medical researchers led by Professor Chris Heeschen developed a new way to detect early-stage cancer tumour cells in the blood using a malaria protein. This method, which targeted individual cancer cells found in a blood sample, also used a magnet to retrieve all the targeted cancer cells.
Professor Gooding believes the two methods, while working on very different scales, would be very complementary as tools to diagnose cancer.
“The malaria protein technology works by detecting cancer cells, rare cells in particular. These are found in the blood also and so are also compatible with the liquid biopsy concept,” he said.
“We are detecting small molecules found in the blood which could also identify the type of cancer, while they are looking for rare cells that are responsible for the spread of cancer. The two technologies could work very well together.”
Receive an email update when we add a new CANCER BLOOD TEST article.
The Latest on: Cancer blood test
via Google News
The Latest on: Cancer blood test
- Roche deepens push into personalized cancer care with new test on September 24, 2018 at 7:22 am
The blood test, called FoundationOne Liquid, is among the first products to emerge from Foundation Medicine after Roche spent $2.4 billion on the testing company earlier this year on the conviction th... […]
- Epic Sciences Announces Publication Showing Blood Test Could Help Select Metastatic Prostate Cancer Patients Who Respond to PSMA-Targeted Therapies on September 24, 2018 at 6:48 am
With further validation the test could be used for patient and therapy matching and an early response measure of drug efficacy in future clinical trials, leading to faster and less expensive drug deve... […]
- Roche aims to improve cancer treatments with DNA blood test on September 24, 2018 at 5:17 am
Roche has launched a blood test that can identify 70 of the most commonly mutated genes in solid tumours, as the company seeks to make more medicine more personalised. The test known as ... […]
- With new blood test, Roche dives deeper into personal cancer care on September 24, 2018 at 12:16 am
ZURICH (Reuters) - Swiss drugmaker Roche upped its bet on personalized cancer treatment on Monday, saying it is now ready to sell a blood test around the world that can identify common gene mutations ... […]
- Roche deepens push into personalised cancer care with new test on September 23, 2018 at 10:35 pm
ZURICH, Sept 24 (Reuters) - Swiss drugmaker Roche upped its bet on personalised cancer treatment on Monday, saying it is now ready to sell a blood test around the world that can identify common cancer ... […]
- University PR misleads with claim that preliminary blood test detects early pancreatic cancer on September 19, 2018 at 8:01 am
The headline of this news release — ‘New blood test detects early stage pancreatic cancer’ — is misleading since the study results are quite preliminary, and the blood test was given to those already ... […]
- New Blood Test That Detects Pancreatic Cancer Early Could Be Available In Two Years on September 19, 2018 at 2:04 am
A new blood test that can detect pancreatic cancer with 96% accuracy at stages one or two could be made available to British patients within a few years. Pancreatic cancer is one of the deadliest form... […]
- New blood test detects early stage pancreatic cancer on September 17, 2018 at 5:35 am
Axial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domain Pancreatic cancer is currently very difficult to detect while it is still resectable. […]
- Researchers develop new blood test to detect early stage pancreatic cancer on September 17, 2018 at 4:06 am
Pancreatic cancer is currently very difficult to detect while it is still resectable. A new blood test developed by researchers at Lund University in Sweden, Herlev Hospital, Knight Cancer Center and ... […]
via Bing News